| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012161624 |
| P356 | DOI | 10.1186/1471-2407-12-569 |
| P932 | PMC publication ID | 3537527 |
| P698 | PubMed publication ID | 23207070 |
| P5875 | ResearchGate publication ID | 233838244 |
| P2093 | author name string | Nelson Adami Andreollo | |
| Cleber Dario Pinto Kruel | |||
| Luis Felipe Ribeiro Pinto | |||
| Danielle Carvalho Quintella | |||
| Ivanir Martins de Oliveira | |||
| Sheila Coelho Soares-Lima | |||
| Paulo Antonio Silvestre de Faria | |||
| Tania Cristina Moita Blanco | |||
| Isabela Martins Gonzaga | |||
| Bruno Souza Bianchi de Reis | |||
| Paulo Thiago Souza de Santos | |||
| Tatiana Almeida de Simão | |||
| P2860 | cites work | EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 |
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study | Q27851683 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| A simple salting out procedure for extracting DNA from human nucleated cells | Q27861086 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Squamous cell carcinoma of the esophagus: a review and update | Q31998185 | ||
| Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry | Q33398141 | ||
| Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis | Q33497634 | ||
| How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? | Q33877216 | ||
| Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck | Q34159125 | ||
| Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer | Q34239801 | ||
| The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities | Q34399306 | ||
| Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials | Q34451337 | ||
| The HER family and cancer: emerging molecular mechanisms and therapeutic targets | Q34558080 | ||
| Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India. | Q34747189 | ||
| Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer | Q35167923 | ||
| Validating cancer drug targets | Q36488747 | ||
| Epidermal growth factor receptor mutation testing in the care of lung cancer patients | Q36542445 | ||
| The complexity of targeting EGFR signalling in cancer: from expression to turnover | Q36556837 | ||
| The Ras/Raf/MAPK pathway | Q36780542 | ||
| STAT-mediated EGFR signaling in cancer. | Q36895477 | ||
| PI3K/PTEN signaling in tumorigenesis and angiogenesis | Q36982971 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| ErbB receptors in the biology and pathology of the aerodigestive tract | Q37263452 | ||
| Mutations and response to epidermal growth factor receptor inhibitors | Q37396680 | ||
| Trastuzumab: in HER2-positive metastatic gastric cancer | Q37809845 | ||
| Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence | Q37826968 | ||
| Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. | Q38934630 | ||
| Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. | Q40213134 | ||
| Correlation of epidermal growth factor receptor mutation, immunohistochemistry, and fluorescence in situ hybridization in esophageal squamous cell carcinoma. | Q43273152 | ||
| An optimized reverse transcription-polymerase chain reaction procedure for the amplification of low-copy Cyp2a3 mRNA in rat esophagus. | Q44519159 | ||
| The HercepTest and routine C-erbB2 immunohistochemistry in breast cancer: any difference? | Q45030721 | ||
| Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer | Q46258371 | ||
| Mutations of the BRAF gene in squamous cell carcinoma of the head and neck | Q47739089 | ||
| Esophageal resection for cancer of the esophagus: long-term function and quality of life. | Q50949088 | ||
| Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. | Q51056791 | ||
| Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations | Q53497225 | ||
| Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. | Q54369328 | ||
| Targeting the epidermal growth factor receptor: a clinical reality | Q74523212 | ||
| EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus | Q81211241 | ||
| Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number | Q81562524 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | esophageal squamous cell carcinoma | Q108442577 |
| P304 | page(s) | 569 | |
| P577 | publication date | 2012-12-04 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas | |
| P478 | volume | 12 |
| Q34084021 | A molecular prognostic model predicts esophageal squamous cell carcinoma prognosis |
| Q36244592 | Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma |
| Q91733327 | Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors |
| Q38951555 | Downregulation of MLL3 in esophageal squamous cell carcinoma is required for the growth and metastasis of cancer cells |
| Q37038482 | Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q90626593 | HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population |
| Q37368954 | Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma |
| Q99565418 | Investigation of HER-2 Expression an Its Correlation with Clinicopathological Parameters and Overall Survival of Esophageal Squamous Cell Carcinoma Patients |
| Q37112504 | Jaridonin, a novel ent-kaurene diterpenoid from Isodon rubescens, inducing apoptosis via production of reactive oxygen species in esophageal cancer cells |
| Q37457633 | MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma. |
| Q28072433 | Molecular targeted therapy for the treatment of gastric cancer |
| Q98199317 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma |
| Q55031644 | Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma. |
| Q38856978 | Synergistic effect of targeting the epidermal growth factor receptor and hyaluronan synthesis in oesophageal squamous cell carcinoma cells. |
| Q38741042 | Targeted therapy in esophageal cancer |
| Q26829483 | The potential of molecular markers to improve interventions through the natural history of oesophageal squamous cell carcinoma |
| Q35624456 | The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma |
| Q57193567 | WNT and NOTCH signaling pathways as activators for epidermal growth factor receptor in esophageal squamous cell carcinoma |
Search more.